(NASDAQ: TPST) Tempest Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Tempest Therapeutics's earnings in 2025 is -$44,799,000.On average, 2 Wall Street analysts forecast TPST's earnings for 2025 to be -$42,685,232, with the lowest TPST earnings forecast at -$47,061,430, and the highest TPST earnings forecast at -$38,308,667. On average, 1 Wall Street analyst forecast TPST's earnings for 2026 to be -$58,992,497, with the lowest TPST earnings forecast at -$58,992,497, and the highest TPST earnings forecast at -$58,992,497.
In 2027, TPST is forecast to generate -$49,086,765 in earnings, with the lowest earnings forecast at -$49,086,765 and the highest earnings forecast at -$49,086,765.